Home - Histogen

Who we are

Managed by highly successful biotech industry veterans, Histogen is a drug development company initially focused on treating infectious diseases by restoring the competence of the human body’s immune system to effectively combat these infections. Histogen is doing this by developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that help restore the body’s natural immune processes that are being attacked by invading organisms.

Our product candidates include emricasan, CTS-2090, and other proprietary caspase inhibitors. Currently, we are developing emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Our pipeline also includes novel preclinical product candidates including CTS-2090 which are highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases.

Emricasan is an orally available pan-caspase inhibitor that effectively reduces inflammation and disease-driven cell damage and death by a process known as apoptosis. Emricasan has been extensively studied in multiple clinical trials involving over 1000 subjects. Emricasan has been chronically dosed for up to 2 -years in immunosuppressed patients and found to be well tolerated. In preclinical models, Emricasan effectively eradicated MRSA bacterial skin infection by a novel host-mediated mechanism of action.